The Spine Journal, the official journal of the North American Spine Society, published a DiscGenics study examining preclinical testing for Discogenic Cells, reports OA Online.
Five insights:
1. Discogenic Cells, biomedically engineered progenitor cells derived from human intervertebral disc tissue, are the active ingredient in IDCT, which is DiscGenics' homologous and allogenic injectable disc cell therapy for disc degeneration.
2. The study shows that intradiscal injection of Discogenic Cells may be used to treat degenerative disc disease, supported by the fact that the cells generate extracellular matrix that may rebuild the diminishing tissue within degenerative discs.
3. Preclinical Discogenic Cells studies demonstrated an ability of "IDCT to safely normalize disc architecture and restore disc height in animal models," according to Flagg Flanagan, CEO and chairman of the board of directors for DiscGenics.
4. If IDCT performs similarly in humans, it may lead to a reduction in pain and disability and provide a significant step forward in the treatment of chronic lumbar pain.
5. Human clinical testing of Discogenic Cells is ongoing in studies in the U.S.
More articles on biologics:
Dr. Isaac Karikari: Changing attitudes toward opioids and how physicians can drive change
Dr. Timothy Kremchek to operate on Reds rookie Nick Senzel — 4 insights
Icotec to introduce new pedicle screw system — 4 insights